ArticleJournal of cardiovascular electrophysiology2026
Incidence of Migraine Following Pulsed-Field Ablation for Atrial Fibrillation: Findings From a Multicenter Analysis.
Article in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew-onset migraine or exacerbation of pre-existent migraine has been reported following catheter ablation for atrial fibrillation (AF). We assessed the incidence of migraine following pulsed-field ablation (PFA).
methodsConsecutive AF patients undergoing PFA using either Farawave or Pulse Select or Sphere 9 catheter systems were included in this multicenter study and prospectively followed up for new migraine or an increase in the severity of the pre-existent headache. Migraine was labeled as "new onset" if the condition was diagnosed for the first time after the index ablation without any previous history, recent or remote. Anti-arrhythmic drugs and oral anticoagulation were prescribed for 2 months after the procedure.
resultsA total of 2148 AF patients undergoing PFA procedures (Farawave: 1477; Pulse Select: 369; and Sphere 9: 392) at the participating centers were included in the analysis. A history of migraine was present in 32 (1.48%) patients, of which 6(18.75%) reported an increase in frequency of migraine in the immediate post-ablation period. New-onset migraine was diagnosed in 31 (1.4%) post-PFA patients. Of these 31 patients, 25 (80.6%) underwent PFA using the Farapulse system, Sphere 9 in 5 (16.12%), and Pulse Select in 1 (3.22%) patient. The incidence of new-onset migraine was comparable between different systems; 1.69% (95% CI 1.10%-2.49%), 1.65% (95% CI 0.54%-3.82%), and 0.27% (95% CI 0.01%-1.50%) for Farapulse, Sphere 9, and Pulse Select, respectively. Mean duration of onset was 3.08 ± 0.67 days post-procedure. In the multivariable regression analysis, BMI was found to be the only predictor of new-onset migraine (OR = 1.402; 95% CI 1.002-1.987; p-value = 0.031).
conclusionNew-onset migraine was observed to be uncommon in patients undergoing PFA. Although the incidence rate was comparable among the three platforms analyzed, the Farawave system showed a higher trend. Of note, BMI was an independent predictor of new migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.